Quality of Life in Children Cured of Retinoblastoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00278031 |
Recruitment Status
:
Recruiting
First Posted
: January 18, 2006
Last Update Posted
: October 4, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Retinoblastoma |
Retinoblastoma is the most common eye tumor of children. It can present in one eye (unilateral) or in both eyes (bilateral). The bilateral form is always hereditary.
Retinoblastoma is a highly curable tumor. Using a combination of surgery, chemotherapy, radiation and local treatment modalities to the eye, over 98% of patients are cured. This means that most children diagnosed with retinoblastoma will become long-term survivors.
The use of surgery (taking out one eye), chemotherapy, and radiation may be associated with long term side-effects, some of which may have significant impact on the quality of life of the child. In addition, in case where the disease is hereditary, additional psychological issues arise.
The aim of our study is to assess, in a comprehensive and standardized fashion, the long term quality of life in children who were treated for retinoblastoma, and who are currently alive and well.
The assessment will include the use of questionnaires that assess quality of life, as well as participation in age-appropriate activities.
Each child, and his/her parent, will be interviewed and the questionnaires completed. The process will take about one hour for each child. No risk or discomfort to the child is involved.
Study Type : | Observational |
Estimated Enrollment : | 35 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Quality of Life in Children Cured of Retinoblastoma |
Study Start Date : | March 2006 |
Estimated Primary Completion Date : | December 2017 |
Estimated Study Completion Date : | December 2017 |

- Change in quality of life [ Time Frame: Baseline and 5 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Past treatment for retinoblastoma

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00278031
Contact: Michael Weintraub, MD | 972-2-6777408 | michaelw@hadassah.org.il |
Israel | |
Hadassah Medical Organization, Jerusalem, Israel | Recruiting |
Jerusalem, Israel, 91120 | |
Contact: Arik Tzukert, DMD 00 972 2 6776095 arik@hadassah.org.il | |
Contact: Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il | |
Principal Investigator: Michael Weintraub, MD |
Principal Investigator: | Michael Weintraub, MD | Hadassah Medical Organization |
Responsible Party: | Michael Weintraub, DIrector, Pediatric Hematology Oncology, Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00278031 History of Changes |
Other Study ID Numbers: |
qolrb-HMO-CTIL |
First Posted: | January 18, 2006 Key Record Dates |
Last Update Posted: | October 4, 2016 |
Last Verified: | October 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Keywords provided by Michael Weintraub, Hadassah Medical Organization:
Retinoblastoma Quality of life |
Additional relevant MeSH terms:
Retinoblastoma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial |
Neoplasms, Nerve Tissue Retinal Neoplasms Eye Neoplasms Neoplasms by Site Eye Diseases Retinal Diseases |